AirSculpt

Intangibles: moderate. The brand is visible in aesthetics, but outcomes depend heavily on surgeon skill and local execution, leading to mixed reviews and reputational variability.

The AirSculpt method is marketed as patented, yet the company relies on FDA‑cleared devices from third-party manufacturers such as Euromi, and its own disclosures emphasize risks that IP protection may be limited and U.S.-only, which constrains durable differentiation. Switching costs: low.

Patients are one‑time cash-pay and can choose among many liposuction and noninvasive options; surgeons are contractors who can be recruited by rivals. Network effects: none. Cost advantage: limited. Centralized marketing and standardized procedures help, but there is no structural low-cost advantage; marketing remains a high, variable expense.

Efficient scale: weak-to-moderate at the city level, but the market is fragmented with many local alternatives. Overall, competitive advantages are thin and execution dependent, with additional potential headwinds from weight-loss drugs and evolving consumer preferences.